News
![](https://www.qa.mdedge.com/sites/all/modules/contrib/lazyloader/image_placeholder.gif)
Unsure on the best T2D drug choice? Let patients decide
- Author:
- Mitchel L. Zoler, PhD
Serially testing equally viable drug options for people with type 2 diabetes can identify the regimen that works best for each individual patient...
News
![](https://www.qa.mdedge.com/sites/all/modules/contrib/lazyloader/image_placeholder.gif)
Triple threat: Novel agent shows potent T2D weight loss in phase 1
- Author:
- Mitchel L. Zoler, PhD
A novel triple agonist targeting the GIP, GLP-1, and glucagon receptors produced unprecedented weight loss in patients with type 2 diabetes after...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Butt_Jawad_H_Den_ESC22_web.jpg)
Frailty poses no limit to HFpEF meds
- Author:
- Mitchel L. Zoler, PhD
Sacubitril/valsartan worked as well or better in frail patients with HFpEF compared with those less frail. Recent dapagliflozin data show this as...
News
![](https://www.qa.mdedge.com/sites/all/modules/contrib/lazyloader/image_placeholder.gif)
Waist-hip ratio beats BMI for predicting obesity’s mortality risk
- Author:
- Mitchel L. Zoler, PhD
Data from more than 380,000 people in the UK Biobank show waist-to-hip ratio estimated mortality risk from obesity better than BMI or fat mass...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Garvey_W_ Timothy_AL_web.jpg)
‘Game changer’ semaglutide halves diabetes risk from obesity
- Author:
- Mitchel L. Zoler, PhD
Post-hoc analysis of two semaglutide trials in people with obesity showed treatment cut their projected 10-year risk for incident type 2 diabetes...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Crozier_Ian_NZ_web.jpg)
Extravascular ICD surpasses goals in pivotal trial
- Author:
- Mitchel L. Zoler, PhD
A novel “extravascular” ICD that avoids some limitations of prior ICD types surpassed its prespecified efficacy and safety goals in a pivotal...
News
![](https://www.qa.mdedge.com/sites/all/modules/contrib/lazyloader/image_placeholder.gif)
MR and PET perform similarly for assessing CAD
- Author:
- Mitchel L. Zoler, PhD
Head-to-head comparison of rubidium PET and cardiac MR showed comparable performance for identifying coronary obstructions.
News
![](https://www.qa.mdedge.com/sites/all/modules/contrib/lazyloader/image_placeholder.gif)
Albuminuria linked to higher CVD risk in diabetes
- Author:
- Mitchel L. Zoler, PhD
An analysis of more than 74,000 Danish people with type 2 diabetes showed an elevated CVD event rate in those with albuminuria.
News
![](https://www.qa.mdedge.com/sites/all/modules/contrib/lazyloader/image_placeholder.gif)
Dapagliflozin’s HFpEF benefit recasts heart failure treatment: DELIVER
- Author:
- Mitchel L. Zoler, PhD
Results from DELIVER made dapagliflozin the third SGLT2 inhibitor to benefit patients with HFpEF, cementing a new, ejection fraction–agnostic...
Video
![](https://www.qa.mdedge.com/sites/all/modules/contrib/lazyloader/image_placeholder.gif)
DAPA-HF: Dapagliflozin’s HFrEF efficacy confirmed in nondiabetics
- Author:
- Mitchel L. Zoler, PhD
PHILADELPHIA – Further analyses from the DAPA-HF trial showed dapagliflozin cut death and heart failure events...
Video
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/article_teasers/annotation_2019-10-29_165436_1.png)
Flu vaccine cuts infection severity in kids and adults
- Author:
- Mitchel L. Zoler, PhD
Recent U.S. data compiled by the CDC documented that children and adults who received influenza vaccines had fewer severe infections.
Video
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/article_teasers/capture3.png)
Oral beta-lactams provide noninferior postdischarge pyelonephritis treatment
- Author:
- Mitchel L. Zoler, PhD
WASHINGTON – Beta-lactams were noninferior to fluoroquinolones or trimethoprim-...
Video
![](https://www.qa.mdedge.com/sites/all/modules/contrib/lazyloader/image_placeholder.gif)
DAPA-HF results transform dapagliflozin from antidiabetic to heart failure drug
- Author:
- Mitchel L. Zoler, PhD
PARIS – Proof that dapagliflozin significantly helped heart failure patients without diabetes recategorizes the...
Video
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/article_teasers/capture_115.jpg)
Overreliance on DAS scores undermines rheumatoid arthritis management
- Author:
- Mitchel L. Zoler, PhD
MADRID – A rheumatoid arthritis patient says “DAS blindness” now pervades rheumatoid arthritis management and degrades care.
Video
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Image/June-2018/133549_graphic_web.png)
New SLE classification criteria reset disease definition
- Author:
- Mitchel L. Zoler, PhD
A weighted-point system lets new SLE criteria classify patients solely by immunology and nephritis or by new...